BUND FINANCE › Stocks › ALC
Alcon Inc. (ALC)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +10.45% above its 50-day average.
- It is +5.14% above its 200-day average (long-term uptrend).
- It sits at 52% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$8.3B | US$8.7B | US$9.5B | US$9.9B | US$10.4B |
| Net income | US$376.0M | US$335.0M | US$974.0M | US$1.0B | US$980.0M |
| EPS (diluted) | 0.76 | 0.68 | 1.96 | 2.05 | 1.98 |
| Gross margin | 56.1% | 54.5% | 55.5% | 55.6% | 55.2% |
| Operating margin | 7.0% | 7.7% | 11.0% | 14.3% | 13.1% |
| Net margin | 4.5% | 3.8% | 10.3% | 10.3% | 9.4% |
| Free cash flow | US$165.0M | US$472.0M | US$537.0M | US$1.4B | US$1.6B |
| Total debt | US$4.5B | US$5.1B | US$5.1B | US$5.1B | US$5.2B |
| Cash | US$1.6B | US$980.0M | US$1.1B | US$1.7B | US$1.5B |
Compound annual growth: revenue 5.8% · net income 27.1% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 55.3x | 66.8x | 27.1x |
| EV / EBITDA | 14.3x | 20.1x | 16.5x |
| Operating margin | 10.2% | — | 3.6% |
| Net margin | 6.1% | — | -0.0% |
| Debt / equity | 0.44 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Alcon Inc.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative m…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice